SCB 219
Alternative Names: SCB-219; SCB-219MLatest Information Update: 03 Jan 2024
At a glance
- Originator Clover Biopharmaceuticals
- Class Bispecific antibodies; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thrombocytopenia
- Preclinical Idiopathic thrombocytopenic purpura
Most Recent Events
- 28 Dec 2023 Pharmacokinetics, efficacy and adverse events data from a phase I trial in Thrombocytopenia released by Clover Biopharmaceuticals
- 28 Dec 2023 Clover Biopharmaceuticals plans a phase Ib trial in Thrombocytopenia in 2024
- 27 Jun 2022 Clover Biopharmaceuticals plans a phase I trial for Thrombocytopenia (In Adults, In Elderly, Treatment-naive) in June 2022 (NCT05426369)